ArticleFrontiers in psychiatry2026
Quantitative susceptibility mapping of brain iron in adult ADHD.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition that frequently persists into adulthood and is linked to alterations in fronto-striatal circuitry and dopaminergic signaling. Brain iron is essential for dopamine synthesis and neural metabolism and can be indexed Methods: Twenty-five adults with ADHD and 24 healthy controls underwent 3T MRI, including high-resolution QSM. Mean susceptibility was extracted from 89 cortical and subcortical regions of interest. For each ROI, group effects were estimated using linear regression with heteroskedasticity-consistent (HC3) inference. To account for group differences in depressive symptoms, additional models included Beck Depression Inventory (BDI-II) scores. Dimensional associations with ADHD symptoms were tested using covariate-adjusted ROI-symptom correlations for current symptoms (CAARS) and retrospective childhood symptoms (WURS-k). Benjamini-Hochberg false discovery rate (FDR) correction was applied within each analysis across ROIs. Results: No ADHD-control group difference survived FDR correction in any model. At the uncorrected level, adults with ADHD showed lower susceptibility in ventral temporal and posterior midline regions, most consistently in the fusiform gyrus and posterior cingulate cortex (small-to-moderate effect sizes across models). When additionally adjusting for depressive symptoms, nominal group differences remained confined to ventral temporal/temporo-limbic and orbitofrontal regions (fusiform, entorhinal cortex, medial orbitofrontal cortex), but again did not survive FDR. Covariate-adjusted ROI-symptom associations did not meet FDR significance; nominally, higher ADHD symptom burden (particularly impulsivity) was associated with lower susceptibility in posterior midline regions (posterior cingulate, precuneus) and ventral temporal cortex (fusiform). Conclusion: In this adult sample, QSM provided no robust evidence for widespread or regionally specific alterations in brain iron susceptibility in ADHD after multiple-comparison correction. Nevertheless, the reproducible pattern of nominal effects-centered on ventral temporal and default-mode network hub regions-suggests that inter-individual variation in cortical susceptibility may relate to clinical heterogeneity and neurodevelopmental timing rather than constituting a strong diagnostic signature. Larger, medication-stratified and developmentally informed studies are needed to clarify whether subtle iron-related susceptibility patterns track symptom dimensions, treatment exposure, and longitudinal trajectories.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.